Spoiled For Choice? Less Is Much More

This way, That way, The other way - decision / choice concept sign post Alamy We Americans love independence and freedom of choice, believing them essential to our well-being. Yet more choice is not, it turns out, leading to more happiness or success. I believe fewer, better choices for individual investors are what we need. Research shows that a certain amount of autonomy around choice is required to achieve a basic level of happiness. However, after that certain point, more choice actually detracts from personal happiness. Too many choices result in feeling overwhelmed, often leading to the inability to make a decision. Information overload, a term popularized by Alvin Toffler in his 1970 book "Future Shock," takes place when the advantages of diversity and individualization are canceled by the complexity of a buyer's decision-making process. On the surface, it would appear that having more choice is a positive development. However, this hides an underlying problem: When faced with too many options, people have trouble determining the best choice and, as a result, can remain indecisive, unhappy and immobilized. Established finance theory has assumed that investors have little difficulty making financial decisions and are well informed, thoughtful and consistent. It's also assumed that investors are not confused by how information is presented and are not influenced by emotions. Clearly, reality does not match this theory. Behavioral finance, on the other hand, is the study of the psychology of financial decision-making and has led to great insights on how investors actually make decisions. Investors confused or uncertain about how to proceed become immobilized. When too many choices are available, inertia sets in. People fail to take action, even on things they want or have agreed to do. This inertia can act as a barrier to effective financial planning, stopping people from saving and making reasonable allocation decisions and necessary changes to their portfolios. The financial services industry is not necessarily helping investors by devising more investment options. There are currently tens of thousands of mutual funds, variable annuity and 401(k) subaccounts, and exchange-traded funds -- not to mention thousands of individual stocks and bonds and a plethora of "alternative" investments. We've got 401(k) plans with dozens of investment options. People make better decisions with a reasonable or limited number of investment options and the "right" amount and type of information about each of them. The need for diversification is one reason we're offered choices in our 401(k) plans. Investors may understand the importance of diversification, but not knowing how to achieve it, they simply adopt what we commonly call "naive diversification," or the "1/n" approach. Without better understanding, plan participants often simply allocate their funds equally across the range of options provided. For example, I've seen investors allocate 25 percent into each of four "lifestyle" funds, only to end up with the exact same allocation they'd have had if they'd selected the balanced option to begin with. But the effort lent the illusion of diversification. I argue that 20 or so investment options are more than enough to achieve proper diversification. In her book, "The Art of Choosing," Columbia University professor Sheena Iyengar shares a study of shoppers who are given an array of either 24 or only six different flavors of jam to select from. The research showed that "fantastic variety seems to favor browsers over buyers." More people spent time exploring the 24 flavors, but when it came to purchasing jam, the booth displaying just six options enjoyed far more sales. Given fewer choices, people felt they could make an informed decision and complete a purchase. Psychologist Barry Schwartz argues in his book, "The Paradox of Choice: Why More Is Less," that eliminating consumer choices can greatly reduce anxiety for shoppers. Reducing anxiety for investors should increase savings rates and confidence around decisions taken. The recent Dodd-Frank Act included provisions requiring that those who render financial advice to retail investors be held to a fiduciary standard no less strict than that of the Advisors' Act of 1940, which requires all financial advisers to put clients' best interests ahead of their own.

More choice doesn't improve an investor's experience. Fewer, better choices are what we need.

However, the opponents of the fiduciary standard argue that this legislation would reduce investment choices for middle-income and beginning investors. Good! As I mentioned in this column, more choice doesn't improve an investor's experience. Fewer, better choices are what we need. If all financial advisers had to put their clients' best interests first, we would see fewer choices. All the mediocre and poor investment options, which simply clutter up the decision-making process and do not serve the investor, would no longer be available. Fewer, quality options would result in more simplistic portfolio allocations. But simplistic allocations do not have to result in less satisfactory portfolio risk-adjusted returns. Allan S. Roth, adviser and author of "How a Second Grader Beats Wall Street," and Craig Israelsen, author of "7Twelve: A Diversified Investment Portfolio with a Plan," among others, have illustrated the effectiveness of such an approach. Simple portfolios produce similar rates of return to more complex options, are typically available at a lower cost, are low maintenance and involve minimal stress.

Can Coach Turn Things Around?

Coach (COH) continues to go to heck in a handbag today with the stock hitting its lowest price since 2009 amid a raft of analyst downgrades.

At $34.71 Coach shares fell 2.75% intraday after dropping as much as 3.8% to $34.31.

The luxury handbag retailer told analysts at a meeting Thursday to expect a double-digit drop in revenue for the fiscal year ending June, and continued loss of market share.

The company isn’t just sitting on its hands. Coach plans to close 70 of its stores and update others as part of a new branding strategy which Coach said is “centered on the concept of defining modern luxury.” These measures are to include the near elimination of its factory outlet stores and reduced promotional pricing for its products.

The question now: Is a turnaround possible?

Morgan Stanley’s Kimberly C. Greenberger maintained an Underweight rating but cut her target to $29, calling Coach "a fading brand" and warning that "re-positioning will take years to play out." She wrote:

COH is taking steps to stabilize brand damage, we estimate heavy turnaround costs and HQ investments burn FY15 cash. We cut our PT to $29 (15x $1.90 FY15 EPSe) and see further downside despite today’s 9% drop.

Citigroup's Oliver Chen maintained his Neutral rating but reduced his target to $36. He writes:

We like new product which fills missing key voids in bag silhouettes, has improved texture, weight and presentation of leather, evokes the Coach Code with more thrill, & has an improved merchandising/flow strategy which is more customer-centric core/downtown/uptown. But the COH system reboot is a layer cake of risk given complexity of integration of new product, stores, brand elevation, & multi-channel execution.

Others downgrading or cutting targets included William Blair, which downgraded to Market Perform from Outperform; Goldman Sachs cut its target to $30; Barclays and Canaccord cut their targets to $35;. BMO downgraded to Market Perform from Outperform.

Some bulls remains, but not many. Stifel Nicolaus maintains a Buy on Coach, although it cut its target to $47 per share from $65. Nomura kept its Buy rating but cut its target cut to $45 from $50.

Can enough money buy you eternal youth?

eternal youth NEW YORK (CNNMoney) A bath in donkey's milk, the blood of children, tortoise scrotum soup -- the list of anti-aging treatments goes back centuries.

No need to go that far.

It turns out, the best kind of anti-aging treatment is inside one's own body, and the rich are taking advantage of it, exploring the latest research in new technologies, genome mapping and stem cell treatments.

Among them is Oracle billionaire Larry Ellison, a large investor of the Ellison Medical Foundation, which supports research exploring the biology that underlies aging and age-related diseases. And there's billionaire Peter Nygård, who says he wants to live forever (or die trying), and has suggested he's found the keys to immortality in stem cell research.

Some doctors agree that stem cells are a key part of chasing youth.

"If you're a wealthy guy and haven't stored your stem cells, I think you're a total idiot," said Dr. Lionel Bissoon, a New York City physician who sees a number of stressed out, wealthy patients.

They usually come to him with similar problems: "Fatigue, belly fat, erectile dysfunction, tiring very quickly ... all very common with my patients from Wall Street," Bissoon said. The short-term solution to those ailments, he says, is testosterone replacement -- which is relatively affordable at a few hundred dollars a pop -- and IV nutrition.

For the long term he recommends stem cell storage, which works as a sort of rainy day insurance. The cells are extracted, preferably when the patient is on the younger side -- around 30 is said to be a good age -- and can then be used to boost an immune system or help to rebuild damaged organs later.

Dr. Dipnarine Maharaj stores cells at his South Florida Bone Marrow Stem Cell Transplant Institute in Boynton Beach, Fla.

"People are looking! and finding ways to be able to help them to live longer to spend the money they've earned," he said. "They spend their retirement going doctor to doctor, and if we can find ways to prevent that it would be good." His clinic sees executives under a lot of stress, a fast way to damage any immune system.

He agrees that it's important to store cells before they become irreparably damaged. To collect and store stem cells at his clinic costs $15,000 for the initial extraction, which includes a year of storage. After that, storage costs $50 per month.

Stem cells aren't the only high-end solution.

Earlier this year, Malaysian billionaire Tan Sri Lim Kok Thay reportedly became one of the initial financial backers of a new genomics and cell therapy technology company called Human Longevity, dedicated to tackling age-related diseases and expanding the human life span.

Another company, Singapore-based Scéil, says it's the first to transform human cells into nearly any tissue type in the body.

"This technology has the potential to reverse, or even cure diseases and repair damaged tissues of your body," the company told CNNMoney in an email. Scéil attempts to obtain "a complete backup" of your genome from a skin sample and stores it for future use. The program costs $60,000 plus storage fees of $5,000 for 10 years, or $25,000 for a lifetime.

"The aging process can be manipulated," said Sonia Arrison, author of 100 Plus: How the Coming Age of Longevity Will Change Everything, From Careers and Relationships to Family and Faith. "We're just at the beginning. There really is going to be a revolution ... it's going to be possible and not crazy at all to have a human life expectancy of 150 years."

She said that it's already possible to use 3D printers to construct organs, and that process will only get faster and more accessible.

But all that advancement won't be available to all -- at least not at first. "Obviously the rich will get it fi! rst," she! said, comparing 3D printed organ availability to cell phones, which were once cost prohibitive to the masses. Now, six billion of the world's seven billion people have one, according to a U.N. study.

"It's how long is the timeline between the rich getting it and the poor getting it," she said.

Dr. Anthony Atala, who runs the Wake Forest Institute for Regenerative Medicine in Winston-Salem, N.C., is committed to making sure those outside the 1% get fair access to such technologies, so that "printing" organs on demand becomes something everyone can do.

"Part of the automation is making sure we lower the cost of these technologies," he said.

Will Small Cap Obesity Stocks Orexigen Therapeutics (OREX) Gain Your Portfolio Some Weight? ARNA, ETRM & VVUS

Orexigen Therapeutics, Inc (NASDAQ: OREX), like Arena Pharmaceuticals, Inc (NASDAQ: ARNA), EnteroMedics Inc (NASDAQ: ETRM) and VIVUS, Inc (NASDAQ: VVUS), is a speculative small cap obesity drug stock that has the potential for coming up with the next big thing in the treatment of obesity that is increasingly a global problems. I should mention that we have recently added Orexigen Therapeutics to our SmallCap Network Elite Opportunity (SCN EO) portfolio as an extremely speculative biotech bet because its lead obesity drug candidate has the potential to be approved by September 11th of this year.

What is Orexigen Therapeutics, Inc?

Small cap obesity drug Orexigen Therapeutics is a biopharmaceutical company focused on the treatment of obesity whose lead product candidate is NB32 which is believed to reduce appetite, help control cravings, increase metabolism and improve control over eating behaviors. In previous clinical trials involving more than 4,500 people, NB32 has been shown to help people lose weight and keep it off for up to one year. In addition and in these studies, 53% of study participants taking NB32 and 21% of those taking placebo lost five percent or more of their body weight over the 12 month trial duration. Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen Therapeutics's strategy for NB32 is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company has submitted applications for marketing authorization in the United States and Europe, with potential approvals in 2014. If approved, North American partner Takeda Pharmaceuticals will commercialize NB32 in the United States. Orexigen Therapeutics's other product candidate, Empatic, has completed Phase 2 clinical trials as a second late-stage, investigational medication for weight loss.

As for potential obesity peers or performance benchmarks, Arena Pharmaceuticals, Inc is focused on commercializing BELVIQ as a monotherapy for chronic weight management and to explore its therapeutic potential in combination with other drugs and for other indications; EnteroMedics Inc has developed VBLOC® vagal blocking therapy, a first-in-class weight loss treatment for obesity and related co-morbidities that is delivered by a pacemaker-like device called the Maestro® Rechargeable System which is designed to control both hunger and fullness by blocking the primary nerve which regulates the digestive system; and VIVUS, Inc is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health for US, European and other world markets.

What You Need to Know or Be Warned About Orexigen Therapeutics, Inc

Earlier in June, Orexigen Therapeutics announced that the FDA had extended its review of the resubmitted New Drug Application (NDA) for NB32 with the new Prescription Drug User Fee Act (PDUFA) action date being set for September 11, 2014. The FDA had indicated that the review extension is needed to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of cardiovascular (CV) outcomes for NB32. It should be noted that the FDA had refused to approve the drug in 2011, citing concerns about cardiovascular risk while the latest delay sent shares down as much as 20% in part due to the activities of options traders.

Nevertheless, the FDA approved the obesity drugs Qsymia from VIVUS, Inc and Arena Pharmaceuticals, Inc's Belviq even after both of those drugs were initially rejected. However, sales of both obesity drugs have been far below expectations due to limited insurance coverage and high out-of-pocket costs for patients.

That could be an issue for Orexigen Therapeutics because the company has only produced revenues of $3.43M (2013), $3.43M (2012), $4.40M (2011) and $1.23M (2010) for the past four years and net losses of $77.67M (2013), $90.09M (2012), $28.06M (2011) and $51.91M (2010). However, the company still ended March with $155.09M in cash and short term investments to cover $21.66M in current liabilities and $80.97M in long term debt – meaning it won't need to do an equity offering any time soon.  

Otherwise, it should be noted that according to HighShortInterest.com, Orexigen Therapeutics has short interest of 21.48% – meaning it can easily make an outsized move in either direction.

Share Performance: Orexigen Therapeutics, Inc vs. ARNA, ETRM & VVUS

On Wednesday, small cap obesity drug Orexigen Therapeutics fell 0.32% to $6.25 (OREX has a 52 week trading range of $4.59 to $7.84 a share) for a market cap of $727.05 million plus the stock is up 9..5% since the start of the year, down 0.95% over the past year and up 55.5% over the past five years. Here is a look at the long term performance of Orexigen Therapeutics verses other obesity drug stocks like Arena Pharmaceuticals, Inc, EnteroMedics Inc and VIVUS, Inc:

As you can see from the above performance chart, obesity drug stocks ate a good way for investors to quickly cause their portfolios to either gain or loose weight.

Finally, here is a look at the technical charts for Orexigen Therapeutics, Arena Pharmaceuticals, Inc, EnteroMedics Inc and VIVUS, Inc:

The Bottom Line. Again, we view Orexigen Therapeutics as a speculative bet on an FDA approval as shares are bound to jump. However and even if there is an FDA approval, investors will want to be cautious given the performance of obesity stocks in general and their ability to actually produce revenue – despite how many people are now obese. 

SmallCap Network Elite Opportunity (SCN EO) has an open position in OREX. To find out what other open positions SCN EO currently has, and to learn why so many traders and investors are relying on this premium subscription service, click here to find out more.

Congress skeptical about GM changes

Lawmakers grill GM's Barra in D.C.   Lawmakers grill GM's Barra in D.C. NEW YORK (CNNMoney) Mary Barra had a tough time Wednesday convincing Congress that General Motors is changing fast enough to make safer cars.

The automaker's CEO testified before a House panel about the results of a company probe into the decade-long delay in recalling 2.6 million vehicles with a faulty ignition switch. The problem has been blamed for at least 13 deaths.

GM (GM) dismissed 15 employees once the probe was complete, and Barra promised the panel that the company is working to change what the report found to be "a pattern of incompetence and neglect."

"I promised we would hold people accountable and make substantive and rapid changes in our approach to recalls," said Barra. "We have done each of these things and more."

But panel members from both parties were doubtful.

"When I go through this, it looks like a lot more than 15 people should have been terminated," said Rep. Michael Burgess, a Texas Republican.

Rep. Jan Schakowsky, an Illinois Democrat, questioned why no top executive at the company was among those who lost their jobs.

"It's not clear to me that any senior level manager has been held responsible for the GM corporate culture that allowed the ignition switch defect to go unaddressed," she said.

Rep. Fred Upton from Michigan released an e-mail he said was sent by a GM employee to executives in 2005 about a problem with the ignition switch in a 2006 Impala. The car shut off when she hit a pothole.

"I think this is a serious safety problem," the GM employee wrote at the time. "I'm thinking big recall. I was driving 45 mph when I hit the pothole and the car shut off and I had a car driving behind me that swerved around me. I don't like to imagine a customer driving with their kids in the back seat on I-75 in rush hour traffic. I think you should seriously consider changing this part."

Upton pointed out that GM had not recalled that vehicle until two days ago, despite all the attention given to the similar ignition problem tied to 13 deaths. GM said it is aware of eight accidents and six injuries but no deaths tied to this latest recall.

For all kinds of problems, GM has recalled a record 20 million vehicles worldwide in 2014 -- which is only about half over.

Panel members also hammered Barra on the official tally of 13 deaths related to ! the problem. GM only counts those killed in the front seat of cars when air bags did not deploy -- not those killed in the back seat of the same fatal accidents or those killed in side-impact accidents when their cars stalled.

"GM has to rebuild trust. Part of that is being straight forward on the number of deaths that occurred," said Rep. Pete Olson, a Texas Republican.

Barra said it will be up to Kenneth Feinberg, who has been hired by GM to figure out how to compensate victims, and to determine who should be on the list of those injured and killed. She said GM's current list of 13 is not "a complete number."

"We want to get everyone who is affected," she said.

But even the GM plan to compensate victims received some criticism. Rep. Morgan Griffin, a Virginia Republican, objected to the fact that while GM is vowing compensate victims, it is still maintaining in court filings that its 2009 bankruptcy case protects itself from lawsuits from those who don't want to accept that offer.

"If GM truly wants to compensate everybody who's been harmed fully and fairly, they ought to ask their lawyers to stop asking for bankruptcy court protections," he said.

Top 5 Specialty Retail Companies To Watch In Right Now

DELAFIELD, Wis. (Stockpickr) -- Trading stocks that trigger major breakouts can lead to massive profits. Once a stock trends to a new high or takes out a prior overhead resistance point, then it's free to find new buyers and momentum players who can ultimately push the stock significantly higher.

>>5 Toxic Stocks to Sell Before February

One example of a successful breakout trade I flagged recently was specialty retailer Coldwater Creek (CWTR), which I featured in Jan. 24's "5 Stocks Ready to Break Out" 74 cents per share. I mentioned in that piece that shares of CWTR recently formed a double-bottom chart pattern at 66 cents to 67 cents per share. The stock was starting to bounce off those support levels and it was showing relative strength on a big down day. That bounce was starting to push shares of CWTR within range of triggering a big breakout trade above some near-term overhead resistance levels at 82 to 84 cents per share.

Guess what happened? Shares of CWTR didn't wait long to trigger that breakout, since the stock took out those key overhead resistance levels on Jan. 27 with strong upside volume flows. This stock broke out and continued to soar higher with shares of CWTR tagging an intraday high on Jan. 29 of 97 cents per share. That represents a gain of right around 30% from the 74-cent level for anyone who bought the stock in anticipation of that breakout. CWTR has now pulled back to right above its 50-day moving average of 82 cents per share, which could offer another good entry point if that level holds.

Top 5 Specialty Retail Companies To Watch In Right Now: Natural Grocers By Vitamin Cottage Inc (NGVC)

Natural Grocers by Vitamin Cottage, Inc., incorporated on April 9, 2012, is a specialty retailer of natural and organic groceries and dietary supplements. The Company operates within the natural products retail industry. The Company offers products and brands, including a selection of natural and organic food, dietary supplements, body care products, pet care products and books.

The Company offers its customers an average of approximately 18,000 store-keeping units (SKUs) of natural and organic products per store, including an average of approximately 7,000 SKU of dietary supplements. As of June 30, 2012, the Company operated 55 stores in 11 states, including Colorado, Idaho, Kansas, Missouri, Montana, Nebraska, New Mexico, Oklahoma, Texas, Utah and Wyoming, as well as a bulk food repackaging facility and distribution center in Colorado. The size of its stores varies from 5,000 selling square feet to 14,500 selling square feet, and a new store averages 9,500 selling square feet.

Advisors' Opinion:
  • [By John Udovich]

    Small cap Natural Grocers by Vitamin Cottage (NYSE: NGVC) and mid cap Sprouts Farmers Market Inc (NASDAQ: SFM) are taking aim at natural and organic foods supermarket giant Whole Foods Market (NASDAQ: WFM), but do either of these stocks have what it takes to take on the the king of organic retailing? Whole Foods Market was founded in Austin way back in 1978 by a�twenty-five year old college dropout and a twenty-one year old�at a time when there were only a handful of natural or organic�supermarkets in the country. Today, Whole Foods Market�has 364 stores in the United States, Canada and the United Kingdom���which are sometimes referred to as ��hole Wallet��r ��hole Paycheck��given how much it costs to shop there.

  • [By John Udovich]

    Large cap natural and organic foods supermarket giant Whole Foods Market, Inc (NASDAQ: WFM), otherwise known as ��hole Wallet��r ��hole Paycheck,��is not the only player in the natural or organics supermarket space for consumers and investors alike as mid cap Sprouts Farmers Market Inc (NASDAQ: SFM) and small caps Fairway Group Holdings Corp (NASDAQ: FWM) and Natural Grocers by Vitamin Cottage Inc (NYSE: NGVC) are also players in the space. It should be mentioned that Whole Foods Market is down 15.7% since the start of the year and has a downward trending technical chart, but�shares are�still up 13% over the past year, up 426.3% over the past five years and up 3,108.6% since January 1992.

Top 5 Specialty Retail Companies To Watch In Right Now: Puget Technologies Inc (PUGE)

PUGET TECHNOLOGIES, INC., incorporated on March 17, 2010, is a development-stage company. The Company is engaged in the distribution of luxury wool bedding sets produced in Germany. The Company�� product includes Lama Wool, Camel Wool, Cashmere Wool and Merino Wool.

The Company�� Lama Wool is consists of 50% Lama Wool hair, and 50% Merino wool hair. The Camel wool is consists of 50% Camel wool hair, and 50% Merino wool hair. The Cashmere wool is blended with Merino wool.

Advisors' Opinion:
  • [By Peter Graham]

    Small cap stocks Inscor, Inc (OTCMKTS: IOGA), Puget Technologies Inc (OTCBB: PUGE) and PTA Holdings Inc (OTCMKTS: PTAH) have all been getting some attention lately in various investment newsletters or investor alerts. However, two of these small caps have been the subject of paid promotions while the third is getting attention largely because its in the growing marijuana or cannabis business. With that in mind, are these stocks really all that hot or not? Here is a quick reality check:

Hot Building Product Companies For 2015: Ulta Salon Cosmetics and Fragrance Inc (ULTA)

Ulta Salon, Cosmetics & Fragrance, Inc. (Ulta), incorporated on January 9, 1990, is a beauty retailer, which provides one-stop shopping for prestige, mass and salon products and salon services in the United States. During the year ended January 28, 2012 (fiscal 2011), the Company opened 61 new stores. It operates full-service salons in all of its stores. Its Ulta store format includes an open and modern salon area with approximately eight to 10 stations. The entire salon area is approximately 950 square feet with a concierge desk, skin treatment room, semi-private shampoo and hair color processing areas. Each salon is a full-service salon offering hair cuts, hair coloring and permanent texture, with salons also providing facials and waxing.

The Company offers products in the categories, such as cosmetics, which includes products for the face, eyes, cheeks, lips and nails; haircare, which includes shampoos, conditioners, styling products, and hair accessories; salon styling tools, which includes hair dryers, curling irons and flat irons; skincare and bath and body, which includes products for the face, hands and body; fragrance for both men and women; private label, consisting of Ulta branded cosmetics, skincare, bath and body products and haircare, and other, including candles, home fragrance products and other miscellaneous health and beauty products. The Company has combined its three operating segments: retail stores, salon services and e-commerce, into one reportable segment.

The Company competes with Macy��, Nordstrom, Sephora, Bath & Body Works, CVS/pharmacy, Walgreens, Target, Wal-Mart, Regis Corp., Sally Beauty and JCPenney salons.

Advisors' Opinion:
  • [By Dan Caplinger]

    Finally, beyond the Dow, the end of earnings season and M&A activity continued to move stocks. Ulta Salon (NASDAQ: ULTA  ) has soared 15.6% after it released favorable results, including same-store sales gains of 6.7% and a 23% increase in overall revenue. Somewhat weak guidance for the current quarter wasn't enough to slow the stock's advance. Meanwhile, Cooper Tire (NYSE: CTB  ) launched 40% higher after getting a $35 per-share buyout bid from Indian company Apollo Tyres. If companies see value even as the stock market pauses or corrects, then further acquisition activity could well spur the market's bull run onward.

Top 5 Specialty Retail Companies To Watch In Right Now: FTD Companies Inc (FTD)

FTD Companies, Inc. (FTD), incorporated on April 25, 2008, is a floral and gifting company. The Company provides floral, gift and related products and services to consumers and retail florists, as well as to other retail locations offering floral and gift products primarily in the United States, Canada, the United Kingdom, and the Republic of Ireland. The Company operates in one segment, which includes floral and related products and services. Its business uses the FTD and Interflora brands, both supported by the Mercury Man logo. The Company�� portfolio of brands also includes Flying Flowers, Flowers Direct, and Drake Algar in the United Kingdom. On November 1, 2013, United Online, Inc. (United Online) completed the separation of United Online into two independent, publicly traded companies: FTD Companies, Inc. and United Online, Inc.

The Company�� products revenues are derived primarily from selling floral, gift and related products to consumers and the related shipping and service fees. Products revenues also include revenues generated from sales of hard goods, software and hardware systems, cut flowers, packaging and promotional products, and a range of other floral-related supplies to floral network members. Its services revenues related to orders sent through the floral network are variable based on either the number of orders or on the value of orders and are recognized in the period in which the orders.

Advisors' Opinion:
  • [By WWW.DAILYFINANCE.COM]

    BlueOrange Studio/Shutterstock One day out of 365, we pay homage to our sainted mothers. Those of us who are members of this long-suffering, uncomplaining, self-sacrificing class may get some soggy French toast in bed, (don't worry, kids; mom will clean up the kitchen), a chance to read in peace, or perhaps time to indulge in a long, hot bath. Bringing Home the Bacon If you really want to pay back mom for all she's done, get ready to pony up big. A card and some carnations (the official flower of Mother's Day, who knew?) just won't cut it. The cost of replacing mom as nurturer, nurse, cleaner and cook -- according to Insure.com's 2014 Mother's Day salary index -- would run you $62,985 a year, up from $59,862 in 2013. Breaking down the price of having someone else handle her various duties: Cooking and cleaning, $12,230 Child care, $21,736 Homework help, $7,290 Chauffeur, $5,672 Shopping, yard work, party and activity planning, finances, etc., $15,019 And my personal favorite, finding out what the kids are up to (paid in the equivalent value of a private detective), $1,036. Salary.com placed a higher value on moms in its 2014 Mother's Day salary survey, concluding that stay-at-home moms were worth $118,905 and working moms worth $70,107 (this does not include any paid salary from their job), with both groups putting more than 56 hours of overtime at home. These numbers are all up from last year's survey. Cooking It Up in a Pan Mom helps to pay for other things, too. Thanks to the Department of Agriculture, you can see what it costs to raise a child in the U.S. to 18. As of August 2013, the average cost is $241,080. This does not cover college, and hopefully dear old dad is contributing. In 2012, there were 10.3 million single U.S. mothers with children under 18, and one-third of women who gave birth in 2012 were single moms. By becoming moms, women give up time to do other things, what economists call an "opportunity cost." Particularly if your mother st

  • [By John Udovich]

    As we head towards Black Friday, small cap specialty retail stocks United Online, Inc (NASDAQ: UNTD), TravelCenters of America LLC (NYSE: TA) and MarineMax, Inc (NYSE: HZO) have the distinction of being the best performing small cap�specialty retail stocks for this year (according to Finviz.com) with gains of 181.2%, 123.8% and 71.8%, respectively. With those returns in mind, what are these small cap specialty retail stocks doing right and will the performance last through the all important holiday season? Here is what new and existing investors and traders alike need to know or consider:

    United Online, Inc.�A provider of consumer products and services over the Internet, United Online�� Content & Media segment services are online nostalgia (Memory Lane) and online loyalty marketing (MyPoints) while its�primary Communications segment services are Internet access and email (NetZero and Juno). The reason United Online is among the�best performing specialty retail stocks for this year in various stock screening tools like Finviz.com�is actually misleading as the company has just completed the spin off�of subsidiary FTD Companies, a floral and gifts products company acquired in August 2008 for $441 million, as�FTD Companies Inc (NASDAQ: FTD) where United Online shareholders received one share of FTD common stock for every five shares of United Online common stock they hold. In addition, United Online completed�a�one-for-seven reverse stock split of United Online shares.�On Tuesday, small cap United Online, Inc fell 1.01% to $15.72 (UNTD has a 52 week trading range of $11.65 to $62.30 a share) for a market cap of $207.79 million plus the stock is up 181.2% since the start of the year and up 182.2% over the past five years. Meanwhile, the FTD Companies Inc�now has a�market cap of $611.60 and the stock is up almost 6% since October.

Top 5 Specialty Retail Companies To Watch In Right Now: Firstin Wireless Technology Inc (FINW)

Firstin Wireless Technology, Inc., formerly Passionate Pet, Inc., incorporated on September 30, 2010, is a mobile service provider. The Company is a software-based mobile service provider that enables enterprises and business users to make affordable and business-quality international long distance and roaming calls over its hybrid mobile VoIP (HY-mVoIPTM) technology. Its service does not replace a user�� existing wireless service, it augments it with global communication capabilities. The Company's application is free to download, and is available on Apple iPhone, Blackberry and Android smartphones.

The Company provides international long distance and roaming services to enterprises and business travelers over smartphones. Business users need to download the Firstin application onto their smartphones to allow them to place and receive international long distance and roaming calls from anywhere in the world for a fixed monthly fee and unlimited usage. The Company intends to revolutionize business mobile communications by spearheading the enterprise mobile VoIP revolution allowing for anywhere, anytime, business-quality and low-cost voice and data communications over smartphones.

Advisors' Opinion:
  • [By Peter Graham]

    Small cap stocks Bonamour Inc (OTCBB: BONI), Firstin Wireless Technology Inc (OTCMKTS: FINW) and Microchannel Technologies Corp (OTCBB: MCTC) have been attracting attention from variosu investment newsletters lately with at least two of these stocks being the subject of paid promotions. Of course, there is nothing wrong with properly disclosed paid promotions or investor relation types of activities as its up to investors and traders alike to do their due diligence. So how hot are these small cap stocks? Here is a quick reality check that might cool your appetite:

  • [By Peter Graham]

    A look at SofTech, Inc�� financials reveals revenues of $1,375k (most recent reported quarter), $1,558k, $1,458k and $1,772k for the past four quarters along with net losses of $266k (most recent reported quarter), $51k and $14k and net income of $252k. At the end of August, SofTech, Inc had $828k in cash to cover $2,717k in current liabilities and $5,445k in total liabilities. Given the recent Asset Purchase Agreement and the deal with lenders, it would be good to wait for some more financials to see how SofTech, Inc�� balance sheet has improved.

    Firstin Wireless Technology Inc (OTCMKTS: FINW) Has Been Quiet Since February

    Small cap Firstin Wireless Technology is a mobile communications company that is leading the shift to the enterprise mobile VoIP revolution through its mobile telephony platform and apps, including a flagship Firstin solution that allows for anywhere, anytime mobile communications at significant cost reductions. On Friday, Firstin Wireless Technology closed at $0.255 for a market cap of $8.57 million plus FINW is down 3,087.5% over the past year and down 78.7% since August 2011 according to Google Finance.

BBRY: Daniel Loeb Isn’t Your Beacon of Hope

Facebook Logo Twitter Logo LinkedIn Logo Google Plus Logo RSS Logo Charles Sizemore Popular Posts: 3 Stocks That Could Break Your Heart in 2014Bitcoin: It’s a Trade, Not an InvestmentNetflix Is a Great Company, But NFLX Stock Is a Terrible Investment Recent Posts: BBRY: Daniel Loeb Isn’t Your Beacon of Hope Bitcoin: It’s a Trade, Not an Investment Health Care REIT: HCN Combines Megatrends and Dividends View All Posts

BlackBerry (BBRY) has been a value trap that has ensnared more than its share of value hunting investors in recent years — yours truly included. Buying BlackBerry stock will also likely go down in history as the single-worst investing mistake in the otherwise illustrious career of Prem Watsa — the chairman of Fairfax Financial (FRFHF) and the man commonly known as the "Warren Buffett of Canada."

Blackberry 185 BBRY: Daniel Loeb Isn't Your Beacon of HopeAttempting to call the bottom in BlackBerry stock — and ultimately getting burned — appears to be something of a rite of passage.

Now, it's Daniel Loeb's turn.

Loeb's Third Point Capital bought 10 million shares of BBRY stock last quarter, making him BlackBerry's fourth-largest institutional holder.

I should start by saying that Daniel Loeb is no dummy. Although Carl Icahn was more vocal about it, Loeb was the first big-name hedge fund manager to take the opposite side of Bill Ackman's poorly conceived short sale of Herbalife (HLF). Over the past 15 years, he has crushed the S&P 500 by more than 12 percentage points annually.

He's also in good company. Although Watsa is the highest-profile BlackBerry bull, last quarter saw funds managed by Joel Greenblatt, Jim Simons, and Mario Gabelli all initiate new positions in BBRY stock.

So, what's the story here? Did BlackBerry finally get so cheap that it was worth the risk?

Maybe. Even after the surge it has had thus far in 2014, BBRY stock still trades hands for just 0.57 times sales. And according to CEO John Chen, BBRY should be cash-flow positive by the end of this year and officially profitable by the end of the first quarter of 2016.

On paper, BlackBerry stock trades for 1.2 times its accounting book value. But bulls have long argued that BlackBerry's real estate and patent portfolio are vastly understated and that the company could be profitably stripped down and sold for spare parts. I conceded as much in an article last month in which I discussed BBRY stock as a potential asset play.

Still, I'm not buying.

Loeb has a well-deserved reputation as an activist investor that wrings unrealized value out of underperforming companies. But I see BBRY as being too broken for even Daniel Loeb to fix. BlackBerry's handset business is long past the point of no return. Shipments fell 41% last year — a year in which their competitors collectively saw sales rise by 39% — and BlackBerry's global market share is now barely one half of 1%.

The most damning indictment of all? BlackBerry's new high-end phones are even losing market share to in-house rivals; sales of older BlackBerry 7 phones grew to overtake those of BlackBerry 10 phones toward the end of last year.

I know, I know. BBRY is looking past handsets to focus on its future as a software and enterprise services company. I get that. And it sounds good.

There is just one massive problem with it: Virtually all of BlackBerry’s current revenue stream comes from handsets. About 40% of revenues comes from handset sales and 53% comes from services — but most of that are fees that users and carriers pay to access BlackBerry's network … with BlackBerry handsets. If handsets disappear, so do most of BlackBerry's revenues.

In other words, BlackBerry can't afford to continue selling handsets, but it also can't not afford to continue selling handsets.

It's a terrible position to be in, and while I believe that CEO John Chen is making a herculean effort, I don't see a clean way out of this.

So, what is Loeb's game plan? Does he — like Watsa — believe that the company will turn a corner?

I don't think so. My bet is that Loeb is positioning himself to either agitate for BBRY's sale or dismemberment.

Can you profit by riding Loeb's coattails? Maybe. But expect it to be a long, drawn-out affair, and understand that it might backfire spectacularly.

The more prudent move here is to simply walk away.

Charles Lewis Sizemore, CFA, is the editor of Macro Trend Investor and chief investment officer of the investment firm Sizemore Capital Management. Click here to receive his FREE weekly e-letter covering top market insights, trends, and the best stocks and ETFs to profit from today's best global value plays.

Three Unexpected "Buys" (DPS, SIMG, SPG)

Quick - what do Simon Property Group Inc. (NYSE:SPG), Dr. Pepper Snapple Group Inc. (NYSE:DPS), and Silicon Image, Inc. (NASDAQ:SIMG) have in common? If you said absolutely nothing, you'd be about 99% right. There's one common thing between SIMG, SPG, and DPS right now, however. What's that? All three stocks are on my personal "buy" list this week.

Every single week, I run a proprietary sort-and-scan of stocks that meet a strict set of fundamental as well as technical criteria. The goal is to find investing ideas that I wouldn't have otherwise found. Otherwise, it's too easy to fall into the trap of buying popular and well-covered (by the media) stocks rather than digging up my own undiscovered value... where the real opportunities are for investors. Truth be told, most of them end up being worthless. Enough of them look attractive enough, however, to explore as trade candidates. As you may have guessed, Silicon Image, Dr. Pepper Snapple Group, and Simon Property Group were the creme of the crop this week.

Truth be told, while I can appreciate the long-term momentum Dr. Pepper Snapple Group shares have been enjoying since 2010, I feel like DPS shares are a little - ok, a lot - overbought. The stock's quietly hitting all-time highs today, which generally isn't my favorite place to step into any name. On the other hand...

... it can't be denied that the company has done its part on the earnings front to justify record high levels for DPS shares. Dr. Pepper Snapple Group just posted its best quarterly earnings ever ($1.01), and the trailing P/E of 16.01 isn't out of line. It's just a little frothy for this kind of stock. All the same, I'd be willing to wade in.

If the name Silicon Image rings a bell, it might be because the SmallCap Network daily newsletter picked it as one if its hypothetical holdings a few days ago. I can see why they liked it. After a pretty significant pullback in 2011 and 2012, SIMG has been making higher lows, and doing its best to make higher highs. Though erratic, the long-term uptrend since mid-2012 is healthy enough to take a shot on here.

But what about the choppy earnings? SIMG seems like it's posted as many quarterly losses as it has gains since 2008. While the past has been hit and miss, 2014 is expected to be a breakout year for Silicon Image. The forward-looking P/E of 13.1 is based on expected earnings growth of 9% this year and growth of 11.2% next year. It's not a ton of growth, but the company's on pace to swing to a trailing-twelve-month profit sometime in the first half of 2014, and the market could go nuts if and when that happens. In fact, the chart says the market is already starting to whisper.

Last but not least, Simon Property Group may not be a bargain at a trailing P/E of 37.5, but it is making progress on the income front. In fact, as the EPS line on the chart below clearly shows, SPG is making very rapid progress in terms of income.

The reason SPG is such a compelling buy right now is the tumble the stock took in the middle of last year. That dip simply lowered the price, and if you look closely at the chart of Simon Property Group, you'll see it's finally shrugged off that weakness and is all the way back in a bulls track. For perspective, though it's not shown on the chart, shares crossed above their 200-day moving average line this week.

For more trading ideas and insights like these, be sure to sign up for the free SmallCap Network newsletter. You'll get stock picks, market calls, and more, every day. Here's what you've missed recently.

Dr Pepper Snapple Group Inc. Beats Estimates; Offers Strong Guidance; Shares Surge (DPS)

Shares of Dr Pepper Snapple Group Inc. (DPS) surged on Wednesday morning after the company offered full year guidance above analyst estimates.

DPS Earnings in Brief

DPS reported Q4 net income of $156 million, or 78 cents per share, down from $170 million, or 81 cents per share, a year ago. Excluding special items, earnings were 97 cents per share, above analysts’ estimate of 85 cents per share. Revenue dipped to $1.46 billion from $1.48 billion last year. Analysts expected to see revenue of $1.47 billion. Looking ahead, the company expects to see full year earnings between $3.38  and $3.46 per share, which would beat analysts’ expectations of $3.27 per share.

CEO Commentary

DPS President and CEO Larry Young commented: "I am proud of the team's ability to remain focused and execute against our strategy during a challenging year. We continued to gain distribution and availability across our key brands and packages and grew volume share and held dollar share in the highly competitive CSD category."

DPS Dividend

DPS declared its last quarterly dividend of 41 cents on February 6. This dividend will be payable on April 4 to shareholders of record on March 17. The stock will go ex-dividend on March 13. This latest dividend is an 8% increase from the company’s last quarterly dividend.

Stock Performance

Dr Pepper Snapple shares were up $4.09, or 8.36%, during pre-market trading Wednesday. The stock is has been mostly flat YTD.

5 Ways to Save Money on Your Wedding

Money Jar 04Getty Images Believe it or not, there was a time in this country when the standard practice for a wedding was to have a small, intimate ceremony, followed by cake and a champagne toast at the local hall or country club. It was a simple affair that could be accomplished with minimal planning and at a reasonable cost. Oh, how times have changed. Today, the average length of an engagement is 14 months, which culminates in a wedding "event" that typically includes 140 guests, 10 bridesmaids and groomsmen, and costs over $28,000. And in some highly populated areas like Manhattan or Los Angeles, the median cost of a wedding tops the $75,000 mark. This might not be a problem in other cultures where money is the standard wedding gift. Those gifts not only helps the newlyweds pay for their weddings, whats left often leaves them with a nice nest egg to build their new life together. Unfortunately, tradition in the United States involves showering the bride and groom with much less practical gifts, such as fancy dishes and fondue sets. The failure of our gift-giving etiquette to evolve as the costs associated with getting married skyrocketed may soon require the traditional statement of "I now pronounce you husband and wife" to be replaced with "I now pronounce you deep in debt." So how can a budget-minded couple create a day to remember -- one that won't break the bank -- without resorting to paper flowers and hand-me-down gowns? Here are a few suggestions that take a little planning and a bit of creativity, but can save you big bucks on your big day: 1. Combine the ceremony and reception sites. One of the costs that most people don't think about when planning their wedding is vendor travel time. Florists, photographers, caterers, and limousine companies who have to shuttle equipment and employees all over town make sure to factor that into their quotes, so by having your ceremony and reception at the same place, you can bring the cost of their services down significantly. 2. Choose the right photographer. Nobody wants to capture their special day in a bunch of off-centered, out-of-focus shots, but professional photographers can charge thousands for their services and usually retain ownership of the photos. Instead, find a photographer whose work you like, then check to see if she has an assistant who's willing to shoot your wedding instead. Most likely, his style and quality will be on par with the pro, but at a greatly discounted price. And chances are he'll let you keep your photos. 3. Have bigger tables. It doesn't take a rocket scientist to figure out that using bigger tables cuts down on the number of centerpieces and linens you'll need. In addition to saving money, it allows your guests to converse and interact with more people, which creates a livelier event. 4. Curate the bar. Sure, you want your guests to loosen up and have a good time, but do they really need a Long Island iced tea or a Zombie in order to do that? Keeping the bar selection to wine and beer -- a red, a white, and a couple of different craft beers -- will still satisfy the crowd while keeping costs low. And if you want to add an extra, but affordable, twist, create a signature cocktail for the event to throw in the mix. 5. Cut the guest list. Although this might be the most obvious tip, it's also one of the hardest for couples to do. But the fact of the matter is, almost all other costs –- food, beverage, rental equipment, even venue size -- spring from the size of your guest list. The percentage that you cut your guest list will almost mirror the percentage in cost savings you achieve, so before you invite your father's great-uncle or your second cousin, twice removed, who you haven't seen since you were 5, make sure they really justify the expense.

Amira Nature Foods (ANFI) Earnings Report: Will the Shorts Feast Again? ANFI & WILC

The Q4 2014 earnings report for Dubai headquartered specialty Basmati rice stock Amira Nature Foods Ltd (NYSE: ANFI), a potential performance peer of other specialty food stocks like The Chefs Warehouse, Inc (NASDAQ: CHEF) and Israel based G Willi-Food International Ltd (NASDAQ: WILC), is due out before the market opens on Tuesday. Aside from the Amira Nature Foods Ltd earnings report, it should be said that The Chefs Warehouse, Inc reported Q1 2014 on May1st (results were negatively impacted by the severe weather that affected many of our core markets) while G Willi-Food International Ltd reported Q1 2014 earnings on May 28th (results were affected by a decline of consumption by Israeli customers). However, Amira Nature Foods Ltd shares fell as much as 22% after reporting third-quarter earnings back in February plus the stock is the sixth most shorted stock on the NYSE with short interest of 45.30% according to HighShortInterest.com.

What Should You Watch Out for With the Amira Nature Foods Ltd Earnings Report?

First, here is a quick recap of Amira Nature Foods Ltd's recent earnings history from Yahoo! Finance:

Earnings HistoryMar 13Jun 13Sep 13Dec 13
EPS Est 0.24 0.10 0.17 0.28
EPS Actual 0.24 0.21 0.18 0.20
Difference 0.00 0.11 0.01 -0.08
Surprise % 0.00% 110.00% 5.90% -28.60%

 

Back in late February, Amira Nature Foods Ltd reported that third quarter fiscal year end revenue increased 25.1% to $142.5 million and profit after tax increased 85.5% to $7.7 million but EPS actually came up a bit short verses the consensus. As a percentage of revenue, the cost of material increased to 75.4% in the third quarter compared to 73.5% for the same period last year due to increase in raw material prices. The Chairman/CEO commented:

"Based on our year-to-date performance and outlook for the final quarter, we remain confident in our ability to deliver a record year in fiscal 2014 and are raising our annual revenue and EBITDA guidance. Our business will benefit from recently announced key contracts, including the launch of Amira branded products in Reliance Retail Limited stores across India and our acquisition of a German branded business of basmati rice."

This time around and according to the Yahoo! Finance analyst estimates page, the consensus expects revenues of $162.20M and EPS of $0.33 - a decline from the EPS of $0.32 expected thirty days ago and $0.31 expected ninety days ago.

On the news front, the shorts have been trashing Amira Nature Foods Ltd on Seeking Alpha with the following articles that can only be read by subscribers:

Amira Nature Foods: More Questions, Fewer Answers Amira Nature Foods: New Risks Create More Than 50% Downside (This article was "removed from Seeking Alpha pending the resolution to a dispute") Even With A Pullback, Amira Nature Foods Not A Value Story

On the other hand and according to a largely positive article on the Motley Fool, the following "red flags" were mentioned:

Arihaan Capital sees more than 50% downside for Amira on the basis of five factors: auditor resignation; misstatement in SEC filings; undisclosed related party potentially used to inflate margins; discrepancies in financials disclosed to SEC and Ministry of Corporate Affairs in India; and inflated revenue contribution from basmati rice exports.

In May, Jefferies downgraded Amira Nature Foods to Hold saying it will likely take time for the company to restore investor confidence. They also lowered their price target for shares to $15 from $25.

What do the Amira Nature Foods Ltd Charts Say?

The latest technical chart for Amira Nature Foods Ltd (Note: None is available from Finviz) shows a downward trend since around March:

However, a performance chart shows that The Chefs Warehouse, Inc and G Willi-Food International Ltd have given investors less volatility:

Nevertheless, the technical charts for The Chefs Warehouse, Inc and G Willi-Food International Ltd show a clear downtrend for 2014:

What Should Be Your Next Move?

Its really difficult to comment on the whether the accusations being thrown around by the shorts are true or not. What is almost certain though is that the 45.30% short interest will almost certainly cause an outsized move (in one direction or the other) on Amira Nature Foods Ltd shares. 

Facebook beats Street; shares soar

SAN FRANCISCO — Facebook beat Wall Street's fourth-quarter sales and profit forecasts, driven by advances in mobile advertising.

The company also provided evidence that the world's largest social network is still growing, and the percentage of monthly users who log in daily is up slightly, at 62%, compared with 59% a year ago.

"Last quarter was our first quarter where more than 50% of our revenue came from mobile," CEO Mark Zuckerberg said on a conference call.

The social-networking giant reported net income of $780 million on $2.6 billion in revenue in the quarter. Analysts had projected Facebook would report fourth-quarter net income of $703.5 million on $2.3 billion in revenue, according to the survey of estimates from Thomson Reuters

Excluding expenses, Facebook was expected to earn 27 cents per share. On that basis, Facebook reported 31 cents per share.

Shares of Facebook surged 12% to $60.04 in after-hours trading on the news.

Revenue from advertising was up 76% from last year, at $2.34 billion. Payments revenue in the quarter was $241 million.

Monthly active users hit 1.23 billion, up 16% from a year ago.

"The percentage of monthly users who log in daily continues to improve," says Edward Jones analyst Josh Olson.

Facebook has come under the spotlight for teen defections. CFO David Ebersman disclosed on the company's third-quarter earnings call that teens using Facebook declined slightly, triggering anew worries about Facebook's popularity.

Teens are flocking to Instagram, which Facebook purchased for $1 billion, and Snapchat, which the social network offered to buy for $3 billion, but the offer was declined.

On teens, "we don't have any new data to report today," Ebersman said on the earnings conference call.

Teen concerns were amplified by a report in January from iStrategyLabs saying Facebook's U.S. teenage members have plummeted 25.3% in the past three years.

Facebook's mobile usage continues to surge. Mobile mont! hly active users hit 945 million in the quarter, up 39% from a year ago. Mobile represented 53% of fourth-quarter revenue, a 23% year-over-year increase.

Facebook grabbed 18.4% of worldwide mobile ad spending in 2013, up from 5.4% in the year before, according to eMarketer. Rival Google gobbled 53.2% of the worldwide mobile ad market in 2013, up slightly from 52.4% in 2012.

The overall mobile ad market worldwide grew 89% to $16.65 billion in 2013, according to eMarketer, up from $8.8 billion in 2012.

"They are going to need to continue to show new ways to grow," says analyst Olson.

Betting on Brazil? It's an Olympic-size bet

Your neighbor, Sam, is a spur-of-the moment guy. He grabbed a flight to Tahiti and became lifelong friends with Quentin Tarantino at a fish fry. And when he took a flier on a Chinese construction company stock before the Bejing Olympics, he made enough money to back the Tahitian luge team at Sochi next month.

You hate Sam. When you returned from your last whimsical trip, you brought back a pair of crutches and a knee that sounds like you're getting your tires rotated. Still, you're intrigued by Sam's China play. After all, Brazil is hosting the World Cup this year, and the summer Olympics next year. Is there a good Brazilian – or Latin American – stock play?

In a nutshell: There are plenty of ways to invest in Brazil specifically and Latin America generally. But you're probably not going to make a quick killing on any of them. And massive sports events are usually not the best reason to invest in a particular country. "I'm from Toronto, and I remember the 1976 Olympics," says Adam Kutas, manager of Fidelity Latin American Fund. "I think they're still paying for it."

The 2008 Beijing summer Olympics, of course, was an exception. Investing in China in the two years leading up to the Beijing games would have been extremely lucrative: China's market soared 80%, vs. a 0.7% loss for the S&P 500. But you can't lay all the gains in China's market on the Olympics alone, despite China's frenzied $15 building program leading up to the games.

Brazil has considerable spending planned for both the World Cup and the Olympics, but it also has pretty stiff headwinds as well. "Developed markets are living in the 1930s, but emerging markets are living in the 1970s – a period of rising costs and slow growth," says Kutas.

Frederico Sampaio, chief investment officer for Brazilian equities at Franklin Templeton, agrees. "No one expects high growth," he says. Brazilian gross domestic product should grow about 2% this year, and inflation should run at about 6%. "The scenario is that we'! ll have a kind of mediocre year."

Brazil is also suffering from two other problems. The first is its neighbor to the south, Argentina, which saw its currency plunge nearly 15% Thursday. Despite Argentina's rich natural resources and educated populace – at the end of the 19th century it was considered a strong rival to the U.S. – the country's chronic mismanagement often rubs off on its neighbors, at least in the short term.

The other problem, ironically, is China, which shows worrisome signs of slowing. HSBC's survey of manufacturers showed slowing in the last quarter of 2013. The index fell below 50, a sign that the Chinese expansion was faltering. "It's the first contractionary reading in quite a while," says Alec Young, Global Equity Strategist for S&P Capital IQ.

Countries with large exports to China – and Brazil is one – got hit particularly hard. The iShares MSCI Brazil fund (ticker: EWZ) fell 2.51% Thursday on the news.

If you're banking on the growth of Brazil's emerging middle class, you need to be patient. Businesses that cater to the consumer depend on rising incomes, and those are growing slowly. And, says Fidelity's Kutas, the interests of the emerging middle class might not benefit local companies. "You talk to an 18-year-old and ask what he wants to buy, and he'll tell you it's an iPod, not a t-shirt made locally," Kutas says. If consumers are spending money on imported goods and the prices of exports are falling, you have a recipe for slow growth.

Which brings us to one good thing about Brazil: It's reasonably cheap. The Brazilian stock market sells for about 9 times estimated 2014 earnings, vs. about 15 times earnings for the Standard and Poor's 500 stock index, Young says. And the iShares MSCI Brazil fund has a 12-month yield of 3.25%, vs. 1.82% for the SPDR S&P 500 fund.

Finding the right mix of improving growth and low stock prices isn't easy anywhere in Latin America. Mexico, for example, does seem to have improving economic co! nditions,! says Sean Lynch, global investment strategist, global investment strategist, Wells Fargo Private Bank. Its economy is closely tied to the U.S., and U.S. economic growth, while not robust, is improving.

Mexico may begin to allow more foreign investment in its oil industry, which could boost flagging production. And its manufacturing sector is also booming, Lynch says. Companies like Cemex, the Mexican cement company, are worldwide powerhouses.

The drawbacks: Mexico is undergoing an initial public offering boom, which should always be viewed warily. And the stocks there are not cheap, Young warns: They sell at about 16 times 2014 earnings. "It's very expensive," Young warns.

If you're a patient, long-term investor, Latin America does offer a surging middle class and a good commodity play, too. To some extent, you can get exposure to Latin America through multinational companies: You'll see Coca-Cola and McDonald's throughout Latin America.

More adventurous investors might consider a broadly diversified Latin American fund: The four with five-year records are in the chart. If you're considering a single-country fund, you should either be a trader with lots of tolerance for volatility, or someone with relatives in that country. Otherwise, your odds of making big money will be about the same as Tahiti winning the luge this year.

4 Tech Stocks Rising on Unusual Volume

DELAFIELD, Wis. (Stockpickr) -- Professional traders running mutual funds and hedge funds don't just look at a stock's price moves; they also track big changes in volume activity. Often when above-average volume moves into an equity, it precedes a large spike in volatility.

>>5 Stocks With Big Insider Buying

Major moves in volume can signal unusual activity, such as insider buying or selling -- or buying or selling by "superinvestors."

Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst. These types of traders like to get in well before a large spike, so it's always a smart move to monitor unusual volume. That said, remember to combine trend and price action with unusual volume. Put them all together to help you decipher the next big trend for any stock.

>>5 Hated Earnings Stocks You Should Love

With that in mind, let's take a look at several stocks rising on unusual volume recently.

Super Micro Computer

Super Micro Computer (SMCI), together with its subsidiaries, develops and provides high-performance server solutions based on modular and open-standard architecture in the U.S. and internationally. This stock closed up 1.5% at $17.30 in Wednesday's trading session.

Wednesday's Volume: 542,000

Three-Month Average Volume: 183,581

Volume % Change: 230%

>>5 Rocket Stocks to Stomp the S&P in 2014

From a technical perspective, SMCI jumped modestly higher here and broke out into new 52-week-high territory with above-average volume. This stock has been trending sideways and consolidating for the last month and change, with shares moving between $16.24 on the downside and $17.23 on the upside. Shares of SMCI could now be setting up for an extended move higher since the stock is taking out the upper-end of its recent range with strong volume.

Traders should now look for long-biased trades in SMCI as long as it's trending above Wednesday's low of $17.02 or above $16.50 and then once it sustains a move or close above Wednesday's high of $17.44 to its three-year high of $18.89 with volume that's near or above 183,581 shares. If we get that move soon, then SMCI will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $23 to $25.

Citrix Systems

Citrix Systems (CTXS) provides cloud computing solutions that enable IT and service providers to build private and public clouds worldwide. This stock closed up 4.8% at $62.98 in Wednesday's trading session.

Wednesday's Volume: 5.36 million

Three-Month Average Volume: 2.88 million

Volume % Change: 175%

>>4 Stocks Under $10 Making Big Moves

From a technical perspective, CTXS ripped higher here right above its 50-day moving average of $59.49 with strong upside volume. This move is quickly pushing shares of CTXS within range of triggering a major breakout trade. That trade will hit if CTXS manages to take out some near-term overhead resistance levels at $63.44 to its 200-day moving average of $64.69 with high volume.

Traders should now look for long-biased trades in CTXS as long as it's trending above Wednesday's low of $60.11 or above its 50-day at $59.49 and then once it sustains a move or close above those breakout levels with volume that's near or above 2.88 million shares. If that breakout hits soon, then CTXS will set up to re-test or possibly take out its next major overhead resistance levels at $70 to $74.

21Vianet Group

21Vianet Group (VNET) provides carrier-neutral Internet data center services in the People's Republic of China. This stock closed up 4.9% at $23.11 in Wednesday's trading session.

Wednesday's Volume: 1.29 million

Three-Month Average Volume: 681,600

Volume % Change: 125%

>>5 Stocks Set to Soar on Bullish Earnings

From a technical perspective, VNET jumped notably higher here right above some near-term support at $21.59 with above-average volume. This move is quickly pushing shares of VNET within range of triggering a big breakout trade. That trade will hit if VNET manages to take out Wednesday's high of $23.20 to its all-time high at $23.70 with high volume.

Traders should now look for long-biased trades in VNET as long as it's trending above some near-term support at $21.59 and then once it sustains a move or close above those breakout levels with volume that hits near or above 681,600 shares. If that breakout hits soon, then VNET will set up to enter new all-time-high territory, which is bullish technical price action. Some possible upside targets off that move are $27 to $30.

Autobytel

Autobytel (ABTL) operates as an automotive marketing services company in the U.S. This stock closed up 3.6% at $17.05 in Wednesday's trading session.

Wednesday's Volume: 524,000

Three-Month Average Volume: 238,925

Volume % Change: 109%

From a technical perspective, ABTL jumped higher here and broke out into new 52-week-high territory with above-average volume. This stock has been uptrending tremendously strong for the last six months, with shares soaring higher from its low of $5 to its intraday high of $17.63. During that uptrend, shares of ABTL have been consistently making higher lows and higher highs, which is bullish technical price action. Market players should now look for a continuation move higher in the short-term if ABTL manages to take out Wednesday's high of $17.63 with strong volume.

Traders should now look for long-biased trades in ABTL as long as it's trending above Wednesday's low of $16.50 or above $15 and then once it sustains a move or close above $17.63 with volume that hits near or above 238,925 shares. If we get that move soon, then ABTL will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $20 to $23.

To see more stocks rising on unusual volume, check out the Stocks Rising on Unusual Volume portfolio on Stockpickr.

-- Written by Roberto Pedone in Delafield, Wis.


RELATED LINKS:



>>2 Stocks Under $10 Triggering Breakouts



>>5 Big Tech Stocks to Sell Now



>>The Case for a Correction in Stocks

Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including

CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.


Overlooked Small Cap Healthcare Information Stocks: EVDY, FMI & CLRX

Small cap healthcare information stocks Everyday Health Inc (NYSE: EVDY), Foundation Medicine Inc (NASDAQ: FMI) and CollabRx Inc (NASDAQ: CLRX) help consumers and healthcare professionals deal with the increasing amount of information overload that comes with treating or figuring out how to treat patients.

Everyday Health Inc. A leading provider of digital health and wellness solutions, small cap Everyday Health Inc combines premier digital content from leading health brands with sophisticated data and analytics technology to provide a highly personalized and differentiated content experience to its users. During 2013, an estimated average of 43 million consumers and 500,000 healthcare professionals, including one-third of all US physicians, utilized Everyday Health Inc's health and wellness properties each month across multiple channels, including the web, mobile devices, video and social media. At the end of March, Everyday Health Inc priced its IPO of about 7.2 million shares at $14 a share to raise approximately $100.8 million. Then in mid May, shares jumped some 15% after Everyday Health Inc reported a 23% revenue rise to $37.5 million and a net loss on a GAAP basis was $7.8 million verses a net loss of $9.2 million. The CEO commented:

"During the first quarter, we executed well on our strategy of going deeper with existing clients, as evidenced by our strong growth rates in advertising and sponsorship revenue and average revenue per advertiser. We also improved our operating leverage in three key areas – editorial and product, sales and marketing, and data and analytics – which contributed to significant bottom line growth and margin expansion."

On Thursday, Everyday Health Inc fell 3.94% to $17.31 (EVDY has a 52 week trading range of $11.84 to $18.39 a share) for a market cap of $520.89 million plus the stock is up 28.2% for retail investors since the end of March.

Foundation Medicine Inc. A molecular information company dedicated to a transformation in cancer care, small cap Foundation Medicine molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. Foundation Medicine's advantage comes from taking its data and combining it with the latest research and clinical practices to provide information to a doctor about the specific genetic makeup of their patients' cancers and potentially effective treatments using approved drugs or experimental drugs in clinical trials. At the end of May, Foundation Medicine announced new data demonstrating that its FoundationOne® fully informative genomic profile for solid tumors identified genomic alterations that prompted physicians to change therapeutic decisions for 28% of patients tested in a prospective study that is being conducted in partnership with US Oncology. The only issue with the platform (of course) will be getting insurance companies to pay for tests. On Thursday, Foundation Medicine fell 0.26% to $23.07 (FMI has a 52 week trading range of $19.51 to $45.00 a share) for a market cap of $650.39 million plus the stock is down 0.9% since the start of the year and down 34.7% since September 2013.

CollabRx Inc. A recognized leader in cloud-based expert systems to inform health care decision-making, small cap CollabRx Inc uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. There is another SCN article (see: CollabRx + Affymetrix = Wow! (AFFX, CLRX)) that talks more in-depth about how there are more than 100,000 research reports on the topic of cancer and cancer treatments published over the past twelve months plus over 500 new cancer therapies in development that are part of more than 10,000 different clinical trials currently underway. This would be on top of all the information, approved drugs and treatment regimens that are already out there – meaning there is considerable information overload in the cancer space that CollabRx Inc seeks to address. CollabRx Inc has also recently announced the introduction of a new physician resource, CancerRx,™ as an IOS application designed to help oncologists and pathologists navigate the complex landscape of oncology therapeutic options. Ravi Salgia, MD, PhD, professor of Medicine at the University of Chicago and the CollabRx lung cancer Therapy Finder lead clinical advisor, commented:

"The CancerRx app provides physicians and their patients with a clear and high-level understanding of how tumor genetics are being leveraged to inform therapy development through easy to navigate, cancer specific Therapy Finder tools. This resource will allow physicians to consider all possible options in designing an optimal treatment plan for their patients."

On Thursday, CollabRx Inc closed at $2.93 (CLRX has a 52 week trading range of $2.60 to $6.75 a share) for a market cap of $5.90 million plus the stock is down 25.6% since the start of the year, down 22.3% over the past year and up 99.3% over the past five years.